TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. Co.'s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. Co. is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The TCRX average annual return since 2021 is shown above.
The Average Annual Return on the TCRX average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether TCRX average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the TCRX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free TCRX Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
